D

Dynavax Technologies Corp
D

DVAX

10.250
USD
0.10
(0.94%)
مغلق
حجم التداول
23,601
الربح لكل سهم
0
العائد الربحي
-
P/E
-21
حجم السوق
1,230,826,663
أصول ذات صلة
A
AEMD
0.01000
(0.81%)
1.25000 USD
B
BCRX
-0.10000
(-1.11%)
8.94000 USD
H
HRTX
0.05000
(2.31%)
2.21000 USD
L
LPCN
-0.01000
(-0.31%)
3.20000 USD
M
MNKD
-0.02500
(-0.69%)
3.59500 USD
S
SNDX
0.01500
(0.17%)
9.01000 USD
المزيد
الأخبار المقالات

العنوان: Dynavax Technologies Corp

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.